WP
PRME icon

Woodline Partners’s Prime Medicine PRME Stock Holding History

Woodline Partners’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Buy
3,003,904
+591
+0% +$1.96K 0.03% 508
2026
Q1 		$10.5M Buy
3,003,313
+469
+0% +$1.78K 0.04% 500
2025
Q4 		$10.4M Buy
3,002,844
+362
+0% +$1.61K 0.04% 455
2025
Q3 		$16.6M Buy
+3,002,482
New +$12.2M 0.08% 323
2024
Q1 		– Sell
-120,060
Closed -$1.06M – 615
2023
Q4 		$1.06M Buy
+120,060
New +$925K 0.01% 403

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Woodline Partners's PRME Position: Q2 2026 in Review

Woodline Partners increased its Prime Medicine (PRME) stake by 0.02% in Q2 2026, buying an estimated $1.96K and bringing the position to 3,003,904 shares worth $11.1M. The position accounts for 0.03% of the portfolio, ranked #508.

Woodline Partners first reported a position in PRME in Q4 2023 and has held it in 5 quarters since. The position peaked at $16.6M in Q3 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Woodline Partners held 3,003,904 shares of Prime Medicine worth $11.1M as of Q2 2026.
  • Woodline Partners bought 591 Prime Medicine shares in Q2 2026, an estimated $1.96K.
  • Prime Medicine made up 0.03% of Woodline Partners's portfolio in Q2 2026, its #508 holding.
  • Woodline Partners first reported a position in Prime Medicine in Q4 2023 and has held it in 5 quarters since.
  • Woodline Partners's Prime Medicine position peaked at $16.6M in Q3 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.